Patents by Inventor Richard J. Varsolona

Richard J. Varsolona has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220242866
    Abstract: The present invention provides processes for the preparation of 2-fluoroadenine, as well as certain intermediates useful in the preparation of 2?-deoxy-4?-C-ethynyl-2-fluoroadenosine (EFdA): EFdA.
    Type: Application
    Filed: June 18, 2020
    Publication date: August 4, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y.L. Chung, Cynthia Marilyn Hong, Guy R. Humphrey, Kevin M. Maloney, Yingju Xu, Richard J. Varsolona
  • Patent number: 11306080
    Abstract: The present invention provides a novel crystalline form of verubecestat (Crystalline Form II of Verubecestat) and pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an A? pathology and/or a symptom or symptoms thereof. Non-limiting examples of such A? pathologies, including Alzheimer's disease and mild cognitive impairment, are disclosed herein.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 19, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Laura M. Artino, William Morris, Eric Sirota, Richard J. Varsolona
  • Publication number: 20220056045
    Abstract: The instant invention is related to a novel solid form of ceftolozane sulfate (the DMAc solvate of ceftolozane sulfate (Form 3)), compositions comprising ceftolozane sulfate DMAc solvate (Form 3), synthesis of Form 3 and an improved crystallization process using Form 3 to prepare ceftolozane sulfate Form 2. Novel compositions also include ceftolozane sulfate solid Form 3 and/or other crystalline and amorphous solid forms of ceftolozane.
    Type: Application
    Filed: June 1, 2017
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin Matthew Maloney, Eric M. Sirota, Richard J. Varsolona, Donald R. Gauthier, Jr., Hong Ren
  • Publication number: 20220024902
    Abstract: The present application relates to crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl) amino]pyrazole-4-carboxamide and processes for the preparation thereof. The compound is useful for the treatment of JAK-mediated diseases or conditions such as atopic dermatitis.
    Type: Application
    Filed: December 12, 2019
    Publication date: January 27, 2022
    Applicant: Intervet Inc.
    Inventors: Christophe Pierre Alain Chassaing, Xiaoling Jin, Rositza Iordanova Petrova, Richard J. Varsolona, Lorenzo Codan, Edward Cleator, Adrian Goodyear, Jonathan Simmons, Tanja Schweisel
  • Publication number: 20200199117
    Abstract: The present invention provides a novel crystalline form of verubecestat (Crystalline Form II of Verubecestat) and pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an A? pathology and/or a symptom or symptoms thereof. Non-limiting examples of such A? pathologies, including Alzheimer's disease and mild cognitive impairment, are disclosed herein.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 25, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Laura M. Artino, William Morris, Eric Sirota, Richard J. Varsolona
  • Patent number: 10457690
    Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jingjun Yin, Tetsuji Itoh, Jianguo Yin, Bangping Xiang, Kevin R. Campos, Alexei Kalinin, Zhuqing Liu, Melodie Deniz Christensen, Kevin M. Belyk, Richard J. Varsolona, Andrew Brunskill
  • Publication number: 20180179223
    Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 28, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Jingjun Yin, Tetsuji Itoh, Jianguo Yin, Bangping Xiang, Kevin R. Campos, Alexei Kalinin, Zhuqing Liu, Melodie Deniz Christensen, Kevin M. Belyk, Richard J. Varsolona, Andrew Brunskill
  • Publication number: 20140057928
    Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Application
    Filed: October 30, 2013
    Publication date: February 27, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rolf-Stefan BRICKL, Shirlynn CHEN, Jihchin CHUNG, Mayur Suryakant DUDHEDIA, Danping LI, Zhi-Hui LU, Siddharthya MUJUMDAR, Chitra TELANG, Richard J. VARSOLONA, Zeren WANG
  • Patent number: 8598183
    Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: December 3, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf-Stefan Brickl, Shirlynn Chen, Jihchin Chung, Mayur Suryakant Dudhedia, Danping Li, Zhi-Hui Lu, Siddharthya Mujumdar, Chitra Telang, Richard J. Varsolona, Zeren Wang
  • Patent number: 8362035
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: January 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
  • Publication number: 20120270775
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Application
    Filed: July 3, 2012
    Publication date: October 25, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thilo BERKENBUSCH, Carl Alan BUSACCA, Burkhard JAEGER, Richard J. VARSOLONA
  • Patent number: 8232293
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
  • Publication number: 20120122887
    Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Application
    Filed: September 23, 2011
    Publication date: May 17, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rolf-Stefan BRICKL, Shirlynn CHEN, Jihchin CHUNG, Mayur Suryakant DUDHEDIA, Danping LI, Zhi-Hui LU, Siddharthya MUJUMDAR, Chitra TELANG, Richard J. VARSOLONA, Zeren WANG
  • Publication number: 20100093792
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Application
    Filed: September 15, 2009
    Publication date: April 15, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Thilo BERKENBUSCH, Carl Alan BUSACCA, Burkhard JAEGER, Richard J. VARSOLONA
  • Publication number: 20090088571
    Abstract: Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.
    Type: Application
    Filed: December 5, 2008
    Publication date: April 2, 2009
    Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Xiao-jun WANG, Thomas WIRTH, Thomas NICOLA, Li ZHANG, Rogelio Perez FRUTOS, Yibo XU, Dhileepkumar KRISHNAMURTHY, Laurence John NUMMY, Richard J. VARSOLONA, Chris Hugh SENANAYAKE, Jutta KROEBER, Diana REEVES
  • Patent number: 7470795
    Abstract: Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: December 30, 2008
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
    Inventors: Xiao-jun Wang, Thomas Wirth, Thomas Nicola, Li Zhang, Rogelio Perez Frutos, Yibo Xu, Dhileepkumar Krishnamurthy, Laurence John Nummy, Richard J. Varsolona, Chris Hugh Senanayake, Jutta Kroeber, Diana Reeves
  • Publication number: 20040229777
    Abstract: This invention relates to novel crystalline phases of the following Compound (1), methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: 1
    Type: Application
    Filed: March 25, 2004
    Publication date: November 18, 2004
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Michael Kenneth Cerreta, John Andrew Smoliga, Richard J. Varsolona
  • Patent number: 6642237
    Abstract: &ggr;-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: November 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: James R. Tata, Kevin T. Chapman, Joseph Leslie Duffy, Nancy J. Kevin, Yuan Cheng, Thomas A. Rano, Fengqi Zhang, Tracy Huening, Brian Anthony Kirk, Zhijian Lu, Subharekha Raghavan, Fred J. Fleitz, Daniel E. Petrillo, Joseph D. Armstrong, III, Richard J. Varsolona, David Askin, R. Scott Hoerrner, Robert Purick
  • Publication number: 20030176501
    Abstract: The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.
    Type: Application
    Filed: November 13, 2002
    Publication date: September 18, 2003
    Inventors: Richard D. Tillyer, Paul J. Reider, Edward J. J. Grabowski, Feng Xu, Robert M. Wenslow, Jose M. Vega, Richard J. Varsolona
  • Patent number: 6486195
    Abstract: The most thermodynamically stable crystalline form of the benzoic acid salt of 4″-deoxy-4″-epi-methylamino avermectin B1a/B1b as the hemihydrate is obtained by crystallization from organic solvents containing a controlled amount of water.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: November 26, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Raymond Cvetovich, James A. McCauley, Richard Demchak, Richard J. Varsolona